Ilyushin Il-12

Overview

Interleukin-12 (IL-12) is a pro-inflammatory cytokine with a central role in antitumor immunity and immune polarization. It is best known for promoting T helper 1 (Th1) responses, enhancing natural killer (NK) cell and cytotoxic T-cell activity, and stimulating production of interferon and other downstream inflammatory mediators. In cancer biology, IL-12 is often studied as an immunomodulatory payload because it can help reprogram an immunosuppressive tumor microenvironment toward a more immune-activating state.

In the recent literature provided, IL-12 appears primarily as a therapeutic target or engineered cytokine in local delivery systems, including messenger RNA, adeno-associated virus vectors, lipopolymer nanoparticle platforms, and piggyBac transposon constructs. These studies focus on using IL-12 to amplify antigen presentation, strengthen T-cell priming, support NK-cell function, and synergize with radiation therapy or other immune interventions while attempting to limit systemic toxicity.

Focus of Latest Publications

Across the cited studies, IL-12 was investigated as a potent immunostimulatory component in multiple cancer-immunotherapy strategies, especially those designed for local or inducible delivery.

In ovarian cancer, an intraperitoneal mRNA-based immunotherapy was reported to deliver a combination of single-chain interleukins, including IL-12, IL-15, pro-IL-18, and Caspase-1, encapsulated in lipid nanoparticles. The goal was to reprogram the immunosuppressive tumor microenvironment in a syngeneic ID8-Fluc ovarian cancer mouse model. In a related ovarian cancer context, IMNN-001 was described as a platform for local and durable delivery of IL-12 using an expression plasmid and a synthetic lipopolymer delivery system, again emphasizing sustained cytokine exposure within the tumor compartment.

Several studies focused on IL-12 as a local gene-therapy payload. One report described radiotherapy synergizing with an inducible AAV-based immunotherapy platform, where local delivery of a vector encoding inducible IL-12 (AAV-iIL12) enabled efficient cytokine production without significant toxicity. Another study on synthetic super-enhancers used adeno-associated virus vectors to drive glioblastoma-selective expression of cytotoxic and immunomodulatory payloads, including IL-12, producing curative outcomes in a mouse model of aggressive glioblastoma. These findings reinforce the idea that IL-12 can be effective when expression is spatially restricted and combined with other antitumor modalities such as X-ray irradiation.

IL-12 was also used to enhance adoptive cell therapies. In gastric cancer, antigen-induced IL-12 was leveraged by engineering HER2-CAR-T cells with a single-chain recombinant human IL-12 fusion protein (p40/p35) in a piggyBac transposon plasmid. The construct was designed either for constitutive secretion under the EF-1α promoter or for antigen-inducible secretion under the NFAT-IL-2 promoter, with the intent of reprogramming the tumor microenvironment and improving CAR-T-cell function. In hematologic malignancy research, short-term activation of NK cells with IL-12, IL-15, and IL-18 generated cytokine-induced memory-like NK cells that showed enhanced antitumor activity, proliferation, and persistence after adoptive transfer.

Other studies placed IL-12 in broader immune-regulatory contexts. In melanoma, TLR9 or TLR7/8 agonist strategies for arming the sentinel lymph node were associated with release of IL-12 among other cytokines such as TNF, IL-6, IL-10, IFNγ, and CXCL10, indicating activation of dendritic cell subsets and downstream inflammatory signaling. In colorectal cancer, the microbiome-focused review noted that beneficial gut microbes such as Akkermansia muciniphila and Bacteroides fragilis, as well as short-chain fatty acid producers, can prime dendritic cells to produce IL-12, polarize Th1 cells, and reinvigorate CD8+ T cells. This places IL-12 at the intersection of microbiome-driven immune priming and checkpoint blockade responsiveness.

Additional contexts included breast cancer and macrophage biology. In a study of hypoxia-induced exosomal CAMTA1 in MDA-MB-231 cells, IL-12 was measured alongside IL-10 in the setting of M2 macrophage polarization, with CD163 used as a macrophage marker. Although IL-12 was not the primary intervention there, its measurement reflects its relevance as a readout of macrophage immune state. In periodontitis, a systematic review and meta-analysis found IL-12 among cytokines significantly associated with disease, alongside IL-1β, IL-6, IL-17, and TNF-α, suggesting broader inflammatory relevance beyond oncology.

Overall, these studies portray IL-12 as a versatile immune-activating cytokine used to enhance dendritic cell function, promote Th1 and CD8+ T-cell responses, support NK-cell activity, and reshape the tumor microenvironment. The recurring theme is that IL-12 is most useful when delivered locally, inducibly, or in combination with complementary therapies such as radiation therapy, CAR-T cells, mRNA platforms, or microbiome-based immune priming.

Key Publications

• May A novel mRNA-based multi-cytokine strategy to reprogram the peritoneal tumor microenvironment in ovarian cancer. (Journal of nanobiotechnology, 2026, PMID 42116169): "An intraperitoneal mRNA-based immunotherapy delivering a combination of single-chain interleukins (IL), including IL-12, IL-15, pro-IL-18, and Caspase-1, encapsulated in lipid nanoparticles, is administered to reprogram the immunosuppressive tumor microenvironment (TME) in a syngeneic ID8-Fluc ovarian cancer mouse model."
• Dec Sex-based considerations in the choice for a TLR9 or TLR7/8 agonist to arm the sentinel lymph node in early-stage melanoma. (Oncoimmunology, 2026, PMID 42093471): "R848 induced superior cDC subset activation and TNF, IL-6, IL-10, IL-12, IFNγ, and CXCL10 release."
• May Re-arming checkpoint blockade in MSS colorectal cancer: A precision-microbiome playbook from mechanisms to clinic. (Turkish journal of surgery, 2026, PMID 42100955): "Beneficial gut microbes can change this. Akkermansia muciniphila, Bacteroides fragilis, and short-chain fatty acid producers prime dendritic cells to produce interleukin (IL)-12, polarise Th1 cells, and reinvigorate CD8+ T-cells."
• May Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. (Cancer cell, 2026, PMID 41875889): "local delivery of a vector encoding for inducible IL-12 (AAV-iIL12) achieves an efficient production of the cytokine without significant toxicity."
• May Hypoxia‑induced exosomal CAMTA1 promotes radio‑resistance in MDA‑MB‑231 cells by regulating NRG1 to mediate M2 macrophage polarization. (International journal of oncology, 2026, PMID 41891984): "Flow cytometry was used to detect CD163 expression while ELISA measured the levels of IL-10 and IL-12."
• Apr A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan-Tissue Antigen-Presenting Cells Enables Durable in situ mRNA Cancer Immunotherapy. (Advanced materials (Deerfield Beach, Fla.), 2026, PMID 42015497): "Upon intratumoral administration, the LPNP co-delivers mRNAs encoding tumor antigens and IL-12, synergistically reprogramming the TMEs and amplifying APC-mediated T cell priming."
• Apr Antigen-induced IL-12 potentiates piggyBac-engineered HER2-CAR-T cells against gastric cancer. (International immunopharmacology, 2026, PMID 41785602): "Interleukin-12 (IL-12), a potent enhancer of T-cell immunity capable of reprogramming the TME, was leveraged in this study by engineering a single-chain recombinant human IL-12 (rhIL-12) fusion protein (p40/p35) cloned into a piggyBac transposon plasmid under either the elongation factor-1α (EF-1α) promoter (PB-IL-12) for constitutive IL-12 secretion or the NFAT-IL-2 promoter (NFAT-IL-12) for antigen-inducible secretion."
• Apr Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia. (Blood advances, 2026, PMID 41538301): "Short-term activation of natural killer (NK) cells with interleukin-12 (IL-12), IL-15, and IL-18 (IL-12/15/18) gives rise to cytokine-induced memory-like (CIML) NK cells after adoptive transfer, which exhibit enhanced antitumor activity, proliferation, and persistence."
• Apr Synthetic super-enhancers enable precision viral immunotherapy. (Nature, 2026, PMID 41951744): "Moreover, GSC-selective expression of a combination of cytotoxic (HSV-TK and ganciclovir) and immunomodulatory (IL-12) payloads, delivered using adeno-associated virus vectors, as a single treatment led to curative outcomes in a mouse model of aggressive glioblastoma."
• Apr Systemic Cytokine Alterations in Periodontitis Independent of Comorbidities: A Systematic Review and Meta-Analysis. (Aging and disease, 2026, PMID 41910651): "Notably, CCL2, IL-1β, IL-6, IL-17, IL-17A, MMP-8, RANKL and TNF-α remained significantly elevated even in analyses restricted to systemically healthy participants, with additional significant associations observed for IL-12 and IL-33."